Skip to content

Feasibility of HIV Prevention Cohort Studies Among Men Who Have Sex With Men in Sub-Saharan Africa

HPTN 075: Feasibility of HIV Prevention Cohort Studies Among Men Who Have Sex With Men in Sub-Saharan Africa

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03201510
Enrollment
401
Registered
2017-06-28
Start date
2015-06-12
Completion date
2017-08-12
Last updated
2025-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV

Brief summary

This study aims to determine the feasibility of recruiting and retaining men who have sex with men (MSM) in a multi-country prospective cohort study in preparation for human immunodeficiency virus (HIV) prevention studies in sub-Saharan Africa (SSA).

Detailed description

HPTN 075 is an observational cohort study. Participants will be accrued over six months at four sites in SSA using convenience sampling strategies, with no replacement for participants lost to follow-up. Each participant will be followed for 12 months, during which five study visits involving structured HIV behavioral assessments, medical examinations, and collection of biological samples will be conducted (including enrollment and quarterly follow-up visits). Participants who do not complete 12 months of follow-up will be contacted to explore reasons for no longer participating.

Interventions

OTHERObservational

HPTN 075 is an observational study in sub-Saharan MSM

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)
CollaboratorNIH
National Institute of Mental Health (NIMH)
CollaboratorNIH
HIV Prevention Trials Network
Lead SponsorNETWORK

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
MALE
Age
18 Years to 44 Years
Healthy volunteers
Yes

Inclusion criteria

* Biologically male at birth, according to self-report; * 18-44 years old (inclusive); * Willing and able to provide informed consent; * Willing to undergo HIV testing throughout the study and to receive those test results; * Reporting at least one act of anal intercourse in the previous 3 months (12 weeks) with a person reported by the participant to be biologically male; * Able to provide complete locator identification for themselves and at least two other personal contacts; * Willing to participate in all scheduled study assessments, including specimen collection, laboratory assessments, and sample storage; * Committing to not participate in any HIV intervention or vaccine study while participating in HPTN 075; * Planning to remain in the study area for at least one year; * For HIV-uninfected men: All HIV test results at the Screening visit must be non-reactive/negative; * For HIV-infected men (up to 20 per site): All HIV test results at the Screening visit must be reactive/positive. Men who are already on PrEP will not be excluded. Additionally, self- or other-identified transgender women and male sex workers will not be excluded. There will, however, be no specific effort to recruit these groups.

Exclusion criteria

* Unwilling to adhere to study procedures; * Past or current participation in a biomedical and/or behavioral HIV/STI intervention or cohort study, including HIV vaccine studies; however, participation in local/area PrEP demonstration projects does not preclude participation in HPTN 075; * HIV-infected men who report that they are already on ART or in HIV care; * Any other reason or condition that in the opinion of the Investigator of Record (IOR) would interfere with participation, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives. * Men who have discordant HIV test results at Screening (i.e., at least one reactive or positive result and at least one non-reactive or negative result). These men will receive HIV counseling and will be referred for further diagnostic tests and care.

Design outcomes

Primary

MeasureTime frameDescription
Recruitment of approximately 400 participantsJuly 2015-July 2016all 4 sites must collectively recruit 400 participants
Retention of approximately 400 participantsJuly 2015-July 2016at least 90% of participants must be retained

Secondary

MeasureTime frameDescription
HIV incidenceJuly 2015-July 2017Measured by HIV RNA from plasma samples

Countries

Kenya, Malawi, South Africa

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026